Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to IQVIA RDS (India) for conducting the trial of KarXT, ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Zai Lab (ZLAB) reported topline data from a Phase 3 study for KarXT in the treatment of schizophrenia, with plans to file for approval in China in early 2025. Read more here.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

Paolo Banchero tied the Orlando Magic record for points in a half on Monday night, scoring 37 in the first two quarters against the Indiana Pacers. He finished with 50 ...

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative ...

The clinical-stage biopharmaceutical company, Seaport Therapeutics, which uses a unique drug delivery platform originally developed by Monash University, has announced the closing of an oversubscribed ...

The funding will support Seaport’s technology platform, which helps drugs be absorbed more efficiently through the lymphatic ...